Are you over 18 and want to see adult content?
More Annotations
![A complete backup of sarahscribblesenespanol.tumblr.com](https://www.archivebay.com/archive/3090a9b6-963e-4c48-b7a5-20435c4d2e8f.png)
A complete backup of sarahscribblesenespanol.tumblr.com
Are you over 18 and want to see adult content?
![ᐉ Авточасти онлайн с до 30% отстъпка - Sauto.BG](https://www.archivebay.com/archive/ea378cc4-5a87-44ab-926c-9510f663c4c1.png)
ᐉ Авточасти онлайн с до 30% отстъпка - Sauto.BG
Are you over 18 and want to see adult content?
![Watch Nerd³'s Mum kill a man and other LIVE DELIGHTS - Nerd³](https://www.archivebay.com/archive/17bf48cc-716a-4d25-be37-6d33f41d5180.png)
Watch Nerd³'s Mum kill a man and other LIVE DELIGHTS - Nerd³
Are you over 18 and want to see adult content?
![EvrenselFilmizle | Film & Dizi Sitesi](https://www.archivebay.com/archive/d6c13b68-4b1b-4c86-861a-4df11e80e36e.png)
EvrenselFilmizle | Film & Dizi Sitesi
Are you over 18 and want to see adult content?
![Dieta odchudzająca, diety, odchudzanie, fitness – Vitalia.pl](https://www.archivebay.com/archive/2237e6c7-10c1-4310-af7b-a4bfb1c13f69.png)
Dieta odchudzająca, diety, odchudzanie, fitness – Vitalia.pl
Are you over 18 and want to see adult content?
![Welcome to CGS | Center for Genetics and Society](https://www.archivebay.com/archive/a609ed6e-852d-48b6-a932-74e818c1c0f6.png)
Welcome to CGS | Center for Genetics and Society
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of waste-outlet.com](https://www.archivebay.com/archive2/fcb6fae7-be84-4861-8643-ea45ae56c8ec.png)
A complete backup of waste-outlet.com
Are you over 18 and want to see adult content?
![A complete backup of parkett-wohnwelt.de](https://www.archivebay.com/archive2/a8d6c56c-f4f9-4271-96e6-67f76857b928.png)
A complete backup of parkett-wohnwelt.de
Are you over 18 and want to see adult content?
Text
and Safety info.
HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). SPINRAZA® (NUSINERSEN) IN ADULTS *Based on commercial patients, early access patients, and clinical trial participants through December 2020. † Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATIONINSURANCE SUPPORT
Biogen insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA, so you can start treatment as quickly as possible and continue as prescribed by your healthcare provider. SMA 360 | SPINRAZA® (NUSINERSEN) Find information about the potential cost of SPINRAZA and the SMA 360 patient support services program from Biogen. See Safety & PrescribingInfo.
NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). OFFICIAL PATIENT SITE Learn about SPINRAZA, an FDA-approved pediatric & adult treatment from Biogen, including where to find treatment centers. See trial resultsand Safety info.
HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). SPINRAZA® (NUSINERSEN) IN ADULTS *Based on commercial patients, early access patients, and clinical trial participants through December 2020. † Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATIONINSURANCE SUPPORT
Biogen insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA, so you can start treatment as quickly as possible and continue as prescribed by your healthcare provider. SMA 360 | SPINRAZA® (NUSINERSEN) Find information about the potential cost of SPINRAZA and the SMA 360 patient support services program from Biogen. See Safety & PrescribingInfo.
NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
DOSING | SPINRAZA® (NUSINERSEN) IMPORTANT SAFETY INFORMATION. Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs ofthese risks.
SPINRAZA® (NUSINERSEN) SAFETY & SIDE EFFECTS Find information on the SPINRAZA safety profile, including potential side effects of SPINRAZA. See clinical trials, safety & PrescribingInfo.
STARTING SPINRAZA® (NUSINERSEN) Find information about starting SPINRAZA, including tips for talking with your doctor and SMA support available for patients. See Safety &Prescribing Info.
FAQ | SPINRAZA® (NUSINERSEN) SPINRAZA is the first approved therapy for pediatric and adult patients with SMA. The effectiveness of SPINRAZA was established in the longest clinical trial program in SMA to date, which included the pivotal ENDEAR and CHERISH clinical trials. SMA 360 | SPINRAZA® (NUSINERSEN) Find information about the potential cost of SPINRAZA and the SMA 360 patient support services program from Biogen. See Safety & PrescribingInfo.
SUPPORT | SPINRAZA® (NUSINERSEN) IMPORTANT SAFETY INFORMATION. Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs ofthese risks.
ENGLISH - SPINRAZA
A treatment for children and adults with spinal muscular atrophy (SMA) A treatment for children and adults with spinal muscular atrophy(SMA).
HIGHLIGHTS OF PRESCRIBING INFORMATION LABORATORY TESTING In a clinical study (mean treatment exposure 7 months), 17 of 51 (33%) SPINRAZA-treated patients had elevated urine protein, compared to 5 of 25 (20%) sham-control patients. IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION. Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs ofthese risks.
OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
DOSING | SPINRAZA® (NUSINERSEN) The recommended dosage of SPINRAZA is. 12 mg (5 mL) per administration. SPINRAZA is an intrathecal injection, or an injection into the fluid of the spine, by a specially trained HCP. The dosing schedule begins with 4 initial loading doses; the first 3 occur in 14-day intervals and theTREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SPINRAZA® (NUSINERSEN) IN ADULTS have been treated with SPINRAZA*. * Based on commercial patients, early access patients, and clinical trial participants through December 2020. ‡ Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged65 and over
YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4. Study time: 14 months. Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE. Secondary outcomes : Changes in upper limb function at 6, 10, and 14 months, measured on RULM. OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
DOSING | SPINRAZA® (NUSINERSEN) The recommended dosage of SPINRAZA is. 12 mg (5 mL) per administration. SPINRAZA is an intrathecal injection, or an injection into the fluid of the spine, by a specially trained HCP. The dosing schedule begins with 4 initial loading doses; the first 3 occur in 14-day intervals and theTREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SPINRAZA® (NUSINERSEN) IN ADULTS have been treated with SPINRAZA*. * Based on commercial patients, early access patients, and clinical trial participants through December 2020. ‡ Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged65 and over
YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4. Study time: 14 months. Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE. Secondary outcomes : Changes in upper limb function at 6, 10, and 14 months, measured on RULM. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
SPINRAZA® (NUSINERSEN) IN ADULTS *Based on commercial patients, early access patients, and clinical trial participants through December 2020. † Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. SPINRAZA® (NUSINERSEN) SAFETY & SIDE EFFECTS Find information on the SPINRAZA safety profile, including potential side effects of SPINRAZA. See clinical trials, safety & PrescribingInfo.
SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
INSURANCE SUPPORT
After you are prescribed SPINRAZA, you will be connected to your support team, including your Lead Case Manager (LCM). Your LCM can: Investigate your insurance benefits to help you understand your current coverage. Facilitate the prior authorization process for treatment. Provide information in the event of denied insuranceclaims.
SMA 360 | SPINRAZA® (NUSINERSEN) Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION. Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs ofthese risks.
ENGLISH - SPINRAZA
A treatment for children and adults with spinal muscular atrophy (SMA) A treatment for children and adults with spinal muscular atrophy(SMA).
REGISTER - SPINRAZA
I authorize Biogen, and companies working with Biogen, to contact me by mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about Biogen’s products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or HIGHLIGHTS OF PRESCRIBING INFORMATION LABORATORY TESTING In a clinical study (mean treatment exposure 7 months), 17 of 51 (33%) SPINRAZA-treated patients had elevated urine protein, compared to 5 of 25 (20%) sham-control patients. OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. SPINRAZA® (NUSINERSEN) IN ADULTS have been treated with SPINRAZA*. * Based on commercial patients, early access patients, and clinical trial participants through December 2020. ‡ Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged65 and over
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SUPPORT | SPINRAZA® (NUSINERSEN) Support throughout your SPINRAZA journey. With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey. NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric andINSURANCE SUPPORT
After you are prescribed SPINRAZA, you will be connected to your support team, including your Lead Case Manager (LCM). Your LCM can: Investigate your insurance benefits to help you understand your current coverage. Facilitate the prior authorization process for treatment. Provide information in the event of denied insuranceclaims.
LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4. Study time: 14 months. Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE. Secondary outcomes : Changes in upper limb function at 6, 10, and 14 months, measured on RULM. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. SPINRAZA® (NUSINERSEN) IN ADULTS have been treated with SPINRAZA*. * Based on commercial patients, early access patients, and clinical trial participants through December 2020. ‡ Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged65 and over
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SUPPORT | SPINRAZA® (NUSINERSEN) Support throughout your SPINRAZA journey. With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey. NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric andINSURANCE SUPPORT
After you are prescribed SPINRAZA, you will be connected to your support team, including your Lead Case Manager (LCM). Your LCM can: Investigate your insurance benefits to help you understand your current coverage. Facilitate the prior authorization process for treatment. Provide information in the event of denied insuranceclaims.
LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4. Study time: 14 months. Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE. Secondary outcomes : Changes in upper limb function at 6, 10, and 14 months, measured on RULM. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
DOSING | SPINRAZA® (NUSINERSEN) The recommended dosage of SPINRAZA is. 12 mg (5 mL) per administration. SPINRAZA is an intrathecal injection, or an injection into the fluid of the spine, by a specially trained HCP. The dosing schedule begins with 4 initial loading doses; the first 3 occur in 14-day intervals and the STARTING SPINRAZA® (NUSINERSEN) On the day of your treatment, the administrative staff will complete your check-in. Then the clinical staff will prepare you for treatment, and an HCP will administer your first dose of SPINRAZA. After, the administrative staff will check you out and schedule your next appointment. Your SMA360° team will follow up with you after eachdose.
SUPPORT | SPINRAZA® (NUSINERSEN) Support throughout your SPINRAZA journey. With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey.WWW.SPINRAZA.COM
Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
SMA 360 | SPINRAZA® (NUSINERSEN) Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
FAQ | SPINRAZA® (NUSINERSEN) SPINRAZA is the first approved therapy for pediatric and adult patients with SMA. The effectiveness of SPINRAZA was established in the longest clinical trial program in SMA to date, which included the pivotal ENDEAR and CHERISH clinical trials. IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION. Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs ofthese risks.
HIGHLIGHTS OF PRESCRIBING INFORMATION LABORATORY TESTING In a clinical study (mean treatment exposure 7 months), 17 of 51 (33%) SPINRAZA-treated patients had elevated urine protein, compared to 5 of 25 (20%) sham-control patients. OFFICIAL PATIENT SITE Moved Permanently. The document has moved here. OFFICIAL PATIENT SITE Learn about SPINRAZA, an FDA-approved pediatric & adult treatment from Biogen, including where to find treatment centers. See trial resultsand Safety info.
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SPINRAZA® (NUSINERSEN) IN ADULTS *Based on commercial patients, early access patients, and clinical trial participants through December 2020. † Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. SUPPORT | SPINRAZA® (NUSINERSEN) With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey. YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATIONINSURANCE SUPPORT
Biogen insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA, so you can start treatment as quickly as possible and continue as prescribed by your healthcare provider. LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4 Study time: 14 months Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE Secondary outcomes:. Changes in upper limb function at 6, 10, and 14 months, measured on RULM; Changes in walking ability measured on the 6MWT NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). OFFICIAL PATIENT SITE Learn about SPINRAZA, an FDA-approved pediatric & adult treatment from Biogen, including where to find treatment centers. See trial resultsand Safety info.
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SPINRAZA® (NUSINERSEN) IN ADULTS *Based on commercial patients, early access patients, and clinical trial participants through December 2020. † Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. SUPPORT | SPINRAZA® (NUSINERSEN) With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey. YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATIONINSURANCE SUPPORT
Biogen insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA, so you can start treatment as quickly as possible and continue as prescribed by your healthcare provider. LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4 Study time: 14 months Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE Secondary outcomes:. Changes in upper limb function at 6, 10, and 14 months, measured on RULM; Changes in walking ability measured on the 6MWT NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
DOSING | SPINRAZA® (NUSINERSEN) IMPORTANT SAFETY INFORMATION. Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs ofthese risks.
SPINRAZA® (NUSINERSEN) SAFETY & SIDE EFFECTS Find information on the SPINRAZA safety profile, including potential side effects of SPINRAZA. See clinical trials, safety & PrescribingInfo.
SUPPORT | SPINRAZA® (NUSINERSEN) With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey. SMA 360 | SPINRAZA® (NUSINERSEN) Find information about the potential cost of SPINRAZA and the SMA 360 patient support services program from Biogen. See Safety & PrescribingInfo.
IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION. Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs ofthese risks.
HIGHLIGHTS OF PRESCRIBING INFORMATION LABORATORY TESTING In a clinical study (mean treatment exposure 7 months), 17 of 51 (33%) SPINRAZA-treated patients had elevated urine protein, compared to 5 of 25 (20%) sham-control patients.REGISTER - SPINRAZA
I authorize Biogen, and companies working with Biogen, to contact me by mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about Biogen’s products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or OFFICIAL PATIENT SITE Moved Permanently. The document has moved here.ECONSENT FORM
By signing this Authorization, I authorize my/my child's HCP, health insurance company, and pharmacy providers ("Healthcare Entities") to disclose to Biogen, and companies working with Biogen (collectively, "Biogen"), health information relating to my/my child's medical condition, treatment, and insurance coverage for Biogen to provide me/my child with (i) support services (and related OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
YOUR GUIDE TO GETTING STARTED WITH SPINRAZA INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SPINRAZA® (NUSINERSEN) IN ADULTS Hear from adults on SPINRAZA. More than 3200 adults around the world have been treated with SPINRAZA.*. Here are some of their stories. *Based on commercial patients, early access patients, and clinical trial participants through December 2019. Adults on SPINRAZA. QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) CHERISH was a 15-month study in 126 people with later-onset SMA (Type 2 and Type 3), ages 2 to 9 years old. It was a randomized, sham-controlled study, which means individuals were randomly placed into a treated or untreated group. The study evaluated the effect SPINRAZA has on motor function, including upper limb function. GLOSSARY | SPINRAZA® (NUSINERSEN) Atrophy (of skeletal muscle): A reduction in the size of muscle fibers, the strength of the muscle, and the resistance to fatigue. Autosomal recessive disorder: A disorder such as spinal muscular atrophy (SMA) requires 2 copies of an abnormal gene, 1 copy from eachparent, to
OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
YOUR GUIDE TO GETTING STARTED WITH SPINRAZA INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SPINRAZA® (NUSINERSEN) IN ADULTS Hear from adults on SPINRAZA. More than 3200 adults around the world have been treated with SPINRAZA.*. Here are some of their stories. *Based on commercial patients, early access patients, and clinical trial participants through December 2019. Adults on SPINRAZA. QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) CHERISH was a 15-month study in 126 people with later-onset SMA (Type 2 and Type 3), ages 2 to 9 years old. It was a randomized, sham-controlled study, which means individuals were randomly placed into a treated or untreated group. The study evaluated the effect SPINRAZA has on motor function, including upper limb function. GLOSSARY | SPINRAZA® (NUSINERSEN) Atrophy (of skeletal muscle): A reduction in the size of muscle fibers, the strength of the muscle, and the resistance to fatigue. Autosomal recessive disorder: A disorder such as spinal muscular atrophy (SMA) requires 2 copies of an abnormal gene, 1 copy from eachparent, to
SPINRAZA® (NUSINERSEN) SAFETY & SIDE EFFECTS Find information on the SPINRAZA safety profile, including potential side effects of SPINRAZA. See clinical trials, safety & PrescribingInfo.
SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
SMA 360 | SPINRAZA® (NUSINERSEN) Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
FAQ | SPINRAZA® (NUSINERSEN) SPINRAZA is the first approved therapy for pediatric and adult patients with SMA. The effectiveness of SPINRAZA was established in the longest clinical trial program in SMA to date, which included the pivotal ENDEAR and CHERISH clinical trials. THE SMA TREATMENT DISCUSSION GUIDE Considerations to help you find the SMA treatment that’s right for you. Use the following information as a guide for discussions withyour
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP).ENGLISH - SPINRAZA
A treatment for children and adults with spinal muscular atrophy (SMA) A treatment for children and adults with spinal muscular atrophy(SMA).
FOR THE MORE THAN 3200 ADULTS WHO HAVE BEEN TREATED WITH STEPHEN // AGE 38 LATER-ONSET SMA TREATED WITH SPINRAZA STUDY OVERVIEW Individual results may vary based on several factors, includingseverity of
REGISTER - SPINRAZA
I authorize Biogen, and companies working with Biogen, to contact me by mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about Biogen’s products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or HIGHLIGHTS OF PRESCRIBING INFORMATION LABORATORY TESTING In a clinical study (mean treatment exposure 7 months), 17 of 51 (33%) SPINRAZA-treated patients had elevated urine protein, compared to 5 of 25 (20%) sham-control patients. OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
YOUR GUIDE TO GETTING STARTED WITH SPINRAZA INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SPINRAZA® (NUSINERSEN) IN ADULTS Hear from adults on SPINRAZA. More than 3200 adults around the world have been treated with SPINRAZA.*. Here are some of their stories. *Based on commercial patients, early access patients, and clinical trial participants through December 2019. Adults on SPINRAZA. QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) CHERISH was a 15-month study in 126 people with later-onset SMA (Type 2 and Type 3), ages 2 to 9 years old. It was a randomized, sham-controlled study, which means individuals were randomly placed into a treated or untreated group. The study evaluated the effect SPINRAZA has on motor function, including upper limb function. GLOSSARY | SPINRAZA® (NUSINERSEN) Atrophy (of skeletal muscle): A reduction in the size of muscle fibers, the strength of the muscle, and the resistance to fatigue. Autosomal recessive disorder: A disorder such as spinal muscular atrophy (SMA) requires 2 copies of an abnormal gene, 1 copy from eachparent, to
OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
YOUR GUIDE TO GETTING STARTED WITH SPINRAZA INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SPINRAZA® (NUSINERSEN) IN ADULTS Hear from adults on SPINRAZA. More than 3200 adults around the world have been treated with SPINRAZA.*. Here are some of their stories. *Based on commercial patients, early access patients, and clinical trial participants through December 2019. Adults on SPINRAZA. QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) CHERISH was a 15-month study in 126 people with later-onset SMA (Type 2 and Type 3), ages 2 to 9 years old. It was a randomized, sham-controlled study, which means individuals were randomly placed into a treated or untreated group. The study evaluated the effect SPINRAZA has on motor function, including upper limb function. GLOSSARY | SPINRAZA® (NUSINERSEN) Atrophy (of skeletal muscle): A reduction in the size of muscle fibers, the strength of the muscle, and the resistance to fatigue. Autosomal recessive disorder: A disorder such as spinal muscular atrophy (SMA) requires 2 copies of an abnormal gene, 1 copy from eachparent, to
SPINRAZA® (NUSINERSEN) SAFETY & SIDE EFFECTS Find information on the SPINRAZA safety profile, including potential side effects of SPINRAZA. See clinical trials, safety & PrescribingInfo.
SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
SMA 360 | SPINRAZA® (NUSINERSEN) Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
FAQ | SPINRAZA® (NUSINERSEN) SPINRAZA is the first approved therapy for pediatric and adult patients with SMA. The effectiveness of SPINRAZA was established in the longest clinical trial program in SMA to date, which included the pivotal ENDEAR and CHERISH clinical trials. THE SMA TREATMENT DISCUSSION GUIDE Considerations to help you find the SMA treatment that’s right for you. Use the following information as a guide for discussions withyour
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP).ENGLISH - SPINRAZA
A treatment for children and adults with spinal muscular atrophy (SMA) A treatment for children and adults with spinal muscular atrophy(SMA).
FOR THE MORE THAN 3200 ADULTS WHO HAVE BEEN TREATED WITH STEPHEN // AGE 38 LATER-ONSET SMA TREATED WITH SPINRAZA STUDY OVERVIEW Individual results may vary based on several factors, includingseverity of
REGISTER - SPINRAZA
I authorize Biogen, and companies working with Biogen, to contact me by mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about Biogen’s products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or HIGHLIGHTS OF PRESCRIBING INFORMATION LABORATORY TESTING In a clinical study (mean treatment exposure 7 months), 17 of 51 (33%) SPINRAZA-treated patients had elevated urine protein, compared to 5 of 25 (20%) sham-control patients. OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
YOUR GUIDE TO GETTING STARTED WITH SPINRAZA INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SPINRAZA® (NUSINERSEN) IN ADULTS Hear from adults on SPINRAZA. More than 3200 adults around the world have been treated with SPINRAZA.*. Here are some of their stories. *Based on commercial patients, early access patients, and clinical trial participants through December 2019. Adults on SPINRAZA. QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) CHERISH was a 15-month study in 126 people with later-onset SMA (Type 2 and Type 3), ages 2 to 9 years old. It was a randomized, sham-controlled study, which means individuals were randomly placed into a treated or untreated group. The study evaluated the effect SPINRAZA has on motor function, including upper limb function. GLOSSARY | SPINRAZA® (NUSINERSEN) Atrophy (of skeletal muscle): A reduction in the size of muscle fibers, the strength of the muscle, and the resistance to fatigue. Autosomal recessive disorder: A disorder such as spinal muscular atrophy (SMA) requires 2 copies of an abnormal gene, 1 copy from eachparent, to
OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
YOUR GUIDE TO GETTING STARTED WITH SPINRAZA INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SPINRAZA® (NUSINERSEN) IN ADULTS Hear from adults on SPINRAZA. More than 3200 adults around the world have been treated with SPINRAZA.*. Here are some of their stories. *Based on commercial patients, early access patients, and clinical trial participants through December 2019. Adults on SPINRAZA. QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) CHERISH was a 15-month study in 126 people with later-onset SMA (Type 2 and Type 3), ages 2 to 9 years old. It was a randomized, sham-controlled study, which means individuals were randomly placed into a treated or untreated group. The study evaluated the effect SPINRAZA has on motor function, including upper limb function. GLOSSARY | SPINRAZA® (NUSINERSEN) Atrophy (of skeletal muscle): A reduction in the size of muscle fibers, the strength of the muscle, and the resistance to fatigue. Autosomal recessive disorder: A disorder such as spinal muscular atrophy (SMA) requires 2 copies of an abnormal gene, 1 copy from eachparent, to
SPINRAZA® (NUSINERSEN) SAFETY & SIDE EFFECTS Find information on the SPINRAZA safety profile, including potential side effects of SPINRAZA. See clinical trials, safety & PrescribingInfo.
SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
SMA 360 | SPINRAZA® (NUSINERSEN) Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
FAQ | SPINRAZA® (NUSINERSEN) SPINRAZA is the first approved therapy for pediatric and adult patients with SMA. The effectiveness of SPINRAZA was established in the longest clinical trial program in SMA to date, which included the pivotal ENDEAR and CHERISH clinical trials. THE SMA TREATMENT DISCUSSION GUIDE Considerations to help you find the SMA treatment that’s right for you. Use the following information as a guide for discussions withyour
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP).ENGLISH - SPINRAZA
A treatment for children and adults with spinal muscular atrophy (SMA) A treatment for children and adults with spinal muscular atrophy(SMA).
FOR THE MORE THAN 3200 ADULTS WHO HAVE BEEN TREATED WITH STEPHEN // AGE 38 LATER-ONSET SMA TREATED WITH SPINRAZA STUDY OVERVIEW Individual results may vary based on several factors, includingseverity of
REGISTER - SPINRAZA
I authorize Biogen, and companies working with Biogen, to contact me by mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about Biogen’s products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or HIGHLIGHTS OF PRESCRIBING INFORMATION LABORATORY TESTING In a clinical study (mean treatment exposure 7 months), 17 of 51 (33%) SPINRAZA-treated patients had elevated urine protein, compared to 5 of 25 (20%) sham-control patients. OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
YOUR GUIDE TO GETTING STARTED WITH SPINRAZA INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SPINRAZA® (NUSINERSEN) IN ADULTS Hear from adults on SPINRAZA. More than 3200 adults around the world have been treated with SPINRAZA.*. Here are some of their stories. *Based on commercial patients, early access patients, and clinical trial participants through December 2019. Adults on SPINRAZA. SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and THE SMA TREATMENT DISCUSSION GUIDE Considerations to help you find the SMA treatment that’s right for you. Use the following information as a guide for discussions withyour
LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN)SPINRAZA FOR SMA CHERISH was a 15-month study in 126 people with later-onset SMA (Type 2 and Type 3), ages 2 to 9 years old. It was a randomized, sham-controlled study, which means individuals were randomly placed into a treated or untreated group. The study evaluated the effect SPINRAZA has on motor function, including upper limb function. OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
YOUR GUIDE TO GETTING STARTED WITH SPINRAZA INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation SPINRAZA® (NUSINERSEN) IN ADULTS Hear from adults on SPINRAZA. More than 3200 adults around the world have been treated with SPINRAZA.*. Here are some of their stories. *Based on commercial patients, early access patients, and clinical trial participants through December 2019. Adults on SPINRAZA. SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and THE SMA TREATMENT DISCUSSION GUIDE Considerations to help you find the SMA treatment that’s right for you. Use the following information as a guide for discussions withyour
LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN)SPINRAZA FOR SMA CHERISH was a 15-month study in 126 people with later-onset SMA (Type 2 and Type 3), ages 2 to 9 years old. It was a randomized, sham-controlled study, which means individuals were randomly placed into a treated or untreated group. The study evaluated the effect SPINRAZA has on motor function, including upper limb function. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
STARTING SPINRAZA® (NUSINERSEN) On the day of your treatment, the administrative staff will complete your check-in. Then the clinical staff will prepare you for treatment, and an HCP will administer your first dose of SPINRAZA. After, the administrative staff will check you out and schedule your next appointment. Your SMA360° team will follow up with you after eachdose.
SPINRAZA® (NUSINERSEN) SAFETY & SIDE EFFECTS Find information on the SPINRAZA safety profile, including potential side effects of SPINRAZA. See clinical trials, safety & PrescribingInfo.
SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
THE SMA TREATMENT DISCUSSION GUIDE Considerations to help you find the SMA treatment that’s right for you. Use the following information as a guide for discussions withyour
SMA 360 | SPINRAZA® (NUSINERSEN) Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
ENGLISH - SPINRAZA
A treatment for children and adults with spinal muscular atrophy (SMA) A treatment for children and adults with spinal muscular atrophy(SMA).
FOR THE MORE THAN 3200 ADULTS WHO HAVE BEEN TREATED WITH INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION FAQ | SPINRAZA® (NUSINERSEN) SPINRAZA is the first approved therapy for pediatric and adult patients with SMA. The effectiveness of SPINRAZA was established in the longest clinical trial program in SMA to date, which included the pivotal ENDEAR and CHERISH clinical trials.REGISTER - SPINRAZA
I authorize Biogen, and companies working with Biogen, to contact me by mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about Biogen’s products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or * Visit Healthcare Professional Site * Safety Information * Prescribing Information * Prescribing Information en español * Find a Treatment Center * Sign Up for Updates*
* Visit HCP Site
* Safety Info
* Prescribing Info
Toggle navigation
A treatment for children and adults with spinal muscular atrophy(SMA) .
*
*
* Why SPINRAZA
* How SPINRAZA Works * Later-Onset Studies* Early-Onset Study
* Presymptomatic Study* Safety Profile
* TAKING SPINRAZA
* Getting Started
* Dosing
* Find a Treatment Center* SPINRAZA STORIES
* Adults on SPINRAZA * Children on SPINRAZA* What is SMA
* About SMA
* SUPPORT
* Support & Resources* Insurance Support
* SMA360°™
* Events
* FAQs
*
*
A treatment for children and adults with spinal muscular atrophy (SMA) A treatment for children and adults with spinal muscularatrophy (SMA) .
*
* Visit Healthcare Professional Site * Safety Information * Prescribing Information * Prescribing Information en español * Find a Treatment Center * Sign Up for Updates TALK WITH YOUR DOCTOR TO GET STARTED Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy. TALK WITH YOUR DOCTOR TO GET STARTED FOR THE 11,000+ PEOPLE WHO HAVE BEEN TREATED WITH SPINRAZA WORLDWIDE,* VICTORIES ARE PERSONAL. *Based on commercial patients, early access patients, and clinical trial participants through December 2020.CLICK HERE FOR
INFORMATION ABOUT
CORONAVIRUS (COVID-19) DISCOVER SPINRAZA: THE FIRST FDA-APPROVEDTREATMENT FOR SMA
7+ years
Safety and efficacy
evaluated
in the longest
clinical trial in
SMA to date
3x/year
SPINRAZA is DIRECTLY DELIVEREDto
the central nervous system (CNS)where
motor neuron loss begins.After 4
initial loading doses,SPINRAZA is
given 3 times a year. FROM 3 DAYS† TO 80 YEARS OLD‡§ There’s someone from almost every age group who has been treatedwith SPINRAZA.
WATCH SOME OF THEIR STORIES †Includes clinical trial patients. ‡Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. Based on commercial patients in the US (including Puerto Rico) through December 2020. DEMONSTRATED EFFICACY IN PEOPLE WITH EARLY- AND LATER-ONSET SMASEE THE DATA
SAFETY & SIDE EFFECTS The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA.SEE SAFETY PROFILE
HOW SPINRAZA WORKS
SPINRAZA targets an underlying cause of muscle weakness in SMA.SEE HOW IT WORKS
IMPORTANT SAFETY INFORMATION INCREASED RISK OF BLEEDING COMPLICATIONS has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs. INCREASED RISK OF KIDNEY DAMAGE, INCLUDING POTENTIALLY FATAL ACUTE INFLAMMATION OF THE KIDNEY, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk. THE MOST COMMON SIDE EFFECTS OF SPINRAZA INCLUDE lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. BEFORE TAKING SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant. PLEASE SEE FULL PRESCRIBING INFORMATION.
This information is not intended to replace discussions with your healthcare provider.INDICATION
SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION& INDICATION
IMPORTANT SAFETY INFORMATION& INDICATION
IMPORTANT SAFETY INFORMATION INCREASED RISK OF BLEEDING COMPLICATIONS has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.INDICATION
SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION& INDICATION
IMPORTANT SAFETY INFORMATION INCREASED RISK OF BLEEDING COMPLICATIONS has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs. INCREASED RISK OF KIDNEY DAMAGE, INCLUDING POTENTIALLY FATAL ACUTE INFLAMMATION OF THE KIDNEY, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk. THE MOST COMMON SIDE EFFECTS OF SPINRAZA INCLUDE lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. BEFORE TAKING SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant. PLEASE SEE FULL PRESCRIBING INFORMATION.
This information is not intended to replace discussions with your healthcare provider.INDICATION
SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.STAY CONNECTED
Sign up with us to receive the latest news, support information, andupcoming events.
Please enter a valid email address.Why SPINRAZA
How SPINRAZA Works
Later-Onset Studies
Early-Onset Study
Presymptomatic StudySafety Profile
TAKING SPINRAZA
Getting Started
Dosing Find a TreatmentCenter
SPINRAZA STORIES
Adults on SPINRAZA
Children on SPINRAZAWHAT IS SMA
About SMA
Support
Support and ResourcesInsurance Support
SMA360°™
Events
FAQs
* Privacy Policy
* Terms and Conditions* Contact Us
* Privacy Policy
* Terms and Conditions* Contact Us
2021 Biogen. All rights reserved. This site is intended for US residents aged 18 and older.SPZ-US-3384 v3
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0